Glufosfamide (Baxter Oncology)

Curr Opin Investig Drugs. 2002 Oct;3(10):1527-32.

Abstract

Glufosfamide is a sugar phosphamide alkylating agent under development by Baxter Oncology (formerly ASTA Medica) as a potential treatment for cancer. By April 2000, glufosfamide had commenced phase II trials, one of which involved intrathecal administration to patients with carcinomatous meningioma.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents, Alkylating / pharmacology*
  • Clinical Trials as Topic
  • Glucose / analogs & derivatives
  • Humans
  • Ifosfamide / analogs & derivatives
  • Neoplasms / drug therapy
  • Phosphoramide Mustards / metabolism
  • Phosphoramide Mustards / pharmacology*
  • Phosphoramide Mustards / therapeutic use
  • Structure-Activity Relationship

Substances

  • Antineoplastic Agents, Alkylating
  • Phosphoramide Mustards
  • beta-D-glucosylisophosphoramide mustard
  • Glucose
  • Ifosfamide